Conversion of Fed-Batch to Continuous Bioprocess
Watch our on-demand webinar, "Conversion of an Intensified Fed-Batch to an Integrated Continuous Bioprocess".
About the Webinar
Biopharma companies are increasingly recognising the need to switch existing fed-batch processes to Integrated Continuous Bioprocess (ICB) platforms as an alternative to scale-up or scale-out approaches for increasing the output of antibody drug substance. Furthermore, ICB facilities allow greater flexibility and better process economics, helping drive down the cost for overall therapeutic protein production.
Just - Evotec Biologics is collaborating with partners to seamlessly make this transition. In this webinar, we will present a case study in which we performed the rapid conversion of an Intensified Fed-Batch monoclonal antibody process to an Integrated Continuous Bioprocess in less than six months from project start to cGMP batch completion resulting in a 5-fold increase in product mass from the bioreactor while minimizing risks from product quality changes.
Meet Our Speaker
Dr. Brian Follstad joined Just - Evotec Biologics in 2021, and he is currently responsible for the Process Sciences department covering both upstream and downstream process development work at the J.POD facility in Redmond, WA. Previously, he worked at Immunex, Amgen, and Catalent, supporting early and late-stage mammalian cell culture process development and characterization projects as well as platform and technology development initiatives involving high productivity culture process design, novel bioreactor technology applications, media development, protein product quality control, and systems biology. Brian received his PhD in Chemical Engineering from the Massachusetts Institute of Technology with a focus on the analysis of metabolic flux and population heterogeneity in continuous mammalian cell culture.
